-

Applaud Medical Changes Name to Avvio Medical, Ushering in a New Era of Kidney Stone Treatment

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical), a company dedicated to revolutionizing the treatment of urinary stones, today announced a bold step forward with a new name that reflects the Company’s vision for the future.

"Avvio is more than just a new name," stated Paul Molloy, President and Chief Executive Officer of Avvio Medical. "Meaning ‘start’, Avvio embodies the company’s unwavering dedication to propelling the future of kidney stone treatment. This name change signifies our commitment to bringing a novel technology, the AVVIO Acoustic Cavitation Lithotripsy System, to market and transforming the patient experience."

The AVVIO Acoustic Cavitation Lithotripsy System: A Paradigm Shift on the Horizon

The AVVIO Acoustic Cavitation Lithotripsy System utilizes low-pressure ultrasound waves to target patented AVVIO Microbubbles. The expansion and collapse of these microbubbles gently fragment urinary stones, offering an efficient, minimally invasive solution with the potential to:

  • Eliminate the need for anesthesia and X-ray imaging in many cases
  • Significantly expand treatment access, driving greater health equity
  • Provide a more convenient and potentially less stressful experience for patients

About Avvio Medical

Avvio Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

For more information, visit www.avviomed.com/

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

Avvio Medical


Release Versions

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

More News From Avvio Medical

Avvio Medical Receives FDA Breakthrough Device Designation for the Avvio Enhanced Lithotripsy System (ELS)

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company developing next-generation kidney stone treatment technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the Avvio Enhanced Lithotripsy System (ELS). The designation highlights the system’s potential to improve outcomes, reduce complications, and expand access to minimally invasive, anesthesia-sparing kidney stone care for mill...

Avvio Medical Announces New CPT Code for Its Breakthrough Kidney Stone Treatment Technology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a company dedicated to revolutionizing the treatment of urinary stones, is excited to announce that the American Medical Association (AMA) has officially published the early release of a new Category III CPT code for Avvio’s novel kidney stone treatment system. Effective January 1, 2026, CPT code 0991T will be used by healthcare providers and facilities nationwide to report procedures utilizing Avvio Medical’s innovative technology. The new c...

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include:...
Back to Newsroom